CHM.AX down 50% to A$0.001 intraday ASX 24 Mar 2026: what drives the selloff

CHM.AX stock fell sharply intraday on 24 Mar 2026, dropping 50.00% to A$0.001 on the ASX. The move followed thin liquidity and no immediate clinical updates, leaving investors to price in higher execution risk for the biotech. We examine trading details, fundamentals, technicals and a short-term Meyka AI forecast to explain why the stock sits at a new low on the ASX.

Intraday price action and volumes for CHM.AX stock

CHM.AX stock opened at A$0.002 and traded between A$0.001 and A$0.002 before the drop. Volume reached 2,506,803.00 shares versus an average of 4,757,511.00, showing elevated selling pressure but below average liquidity. Market cap sits at A$4,418,704.00, reflecting heavy dilution and a tiny free float on the ASX.

One trade set off a rapid repricing. The one-day change is -50.00%, the one-year change is -80.00%, and three-month performance is -66.67%, underlining persistent downside this year.

Drivers and CHM.AX stock news that link to the selloff

There were no major regulatory rulings or fresh trial data published today, increasing sensitivity to trading flows and short-term sentiment. Biotech peers and the healthcare sector underperformance amplified pressure, leaving Chimeric Therapeutics more exposed to headline risk.

Market participants pointed to low analyst coverage and wide bid-ask spreads as amplifiers. For context on comparable ASX listings in small-cap healthcare, see this sector comparison source.

Fundamentals and valuation metrics for CHM.AX stock

Chimeric Therapeutics (CHM.AX) shows negative earnings and stretched balance metrics. EPS is -0.01 and reported PE is -0.10, reflecting losses. Price averages are A$0.0021 (50-day) and A$0.003085 (200-day), indicating a downtrend versus moving averages.

Key ratios: price-to-sales is 1.24, EV-to-sales is 0.54, and current ratio is 0.69, signalling tight short-term liquidity. Research and development to revenue is 1.65x, consistent with a clinical-stage biotech spending profile.

Technicals, liquidity and trading risks in CHM.AX stock

Technical indicators show oversold momentum. RSI reads 22.35, CCI is -248.23, and ADX is 40.47, indicating a strong downward trend. On-balance volume is negative at -8,474,264.00, confirming distribution.

Low liquidity and wide spreads create execution risk for larger trades. Average volume of 4,757,511.00 contrasts with today’s 2,506,803.00, meaning intraday swings can be magnified on the ASX.

Meyka AI grades and CHM.AX stock analyst context

Meyka AI rates CHM.AX with a score out of 100: 69.79 (Grade B) and suggests HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

This proprietary score balances a weak price trend and thin liquidity against the company’s clinical pipeline. The grade is informational only and not investment advice.

Risks, catalysts and how CHM.AX stock could move next

Primary risks include further dilution, trial setbacks, and continued sector weakness. A lack of near-term earnings catalysts keeps downside risk elevated for ASX holders. Positive catalysts would be favourable phase I readouts, partnership deals, or capital raises that limit dilution.

Watch daily volume, newsflow from Chimeric Therapeutics Limited, and sector momentum for signs of stabilisation on the ASX.

Final Thoughts

Key takeaways: CHM.AX stock trades at A$0.001 on the ASX after a 50.00% intraday fall on 24 Mar 2026. The drop reflects thin liquidity, negative technicals and clinical-stage funding risk rather than a single news catalyst. Meyka AI’s forecast model projects a near-term base-case target of A$0.003 and a conservative downside case of A$0.0005. Versus the current price of A$0.001, the base-case implies an upside of +200.00% and the downside case implies -50.00%. Forecasts are model-based projections and not guarantees. Investors should weigh the high volatility, negative EPS (-0.01) and low current ratio (0.69) before trading CHM.AX. For quick access to live quotes and alerts use our AI-powered market analysis on Meyka AI and monitor official company releases and ASX updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.